Acomplia (rimonabant) is Reimbursed in Switzerland for the Treatment of Type 2 Diabetics Overweight Patients and for the Treatment of Patients with Obesity
ACOMPLIA® is reimbursed by the mandatory social security system for the treatment of type 2 diabetic overweight patients (Body Mass Index - BMI - greater than or equal 28 kg/m2) on at least one oral antidiabetic. ACOMPLIA® is furthermore reimbursed for the treatment of patients with obesity (BMI greater than or equal 35 kg/m2).
ACOMPLIA® will be available at a price similar to those obtained in the countries of the European Union.
In Switzerland, ACOMPLIA® is indicated in association with a light hypocaloric diet and physical activity for obese patients (Body Mass Index - BMI - greater than or equal to 30 kg/m2) or for overweight patients (BMI greater than or equal to 27 kg/m2) with at least one associated cardiovascular risk factor, when measures taken to reduce weight, such as diet and/or physical activity turned out to be insufficient.
ACOMPLIA® is the first member of a new therapeutic class: the CB1 receptor antagonists. The marketing authorisation is based on a thorough analysis of the safety and efficacy results and the assessment of the pivotal clinical trial program of the phase III. These results have shown that ACOMPLIA® at 20 mg per day (1 tablet) significantly reduces weight, waist circumference, HBA1c, triglycerides, at the same time improving significantly the patients’ HDL ("good cholesterol").
Sanofi-aventis is one of the world leaders in the pharmaceutical industry, ranking number one in Europe. Backed by a world-class R&D organisation, sanofi-aventis is developing leading positions in seven major therapeutic areas: cardiovascular, thrombosis, oncology, metabolic
diseases, central nervous system, internal medicine and vaccines. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Forward Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include financial projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future events, operations, products and services, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “plans” and similar expressions. Although sanofi-aventis’ management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in sanofi-aventis’ annual report on Form 20-F for the year ended December 31, 2006. Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements.
Posted: April 2007